Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 13/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 13/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285781 | 1.00 | CDK9 (0.42) | CDK9CCNT1SMN1; SMN2LMNA | |
| SCHEMBL1462530 | 0.93 | CCNT1 (0.47) | CDK9CCNT1SMN1; SMN2LMNA | |
| SCHEMBL1464297 | 0.93 | CCNT1 (0.47) | CDK9CCNT1SMN1; SMN2LMNA | |
| SCHEMBL1945132 | 0.93 | CCNT1 (0.47) | CDK9CCNT1SMN1; SMN2LMNA | |
| SCHEMBL1948331 | 0.93 | CCNT1 (0.47) | CDK9CCNT1SMN1; SMN2LMNA | |
| SCHEMBL10242077 | 0.87 | CDK9 (0.44) | CDK9CCNT1SMN1; SMN2 | |
| SCHEMBL10242098 | 0.87 | CDK9 (0.44) | CDK9CCNT1SMN1; SMN2 | |
| SCHEMBL10285428 | 0.86 | CCNT1 (0.41) | CDK9CCNT1 | |
| SCHEMBL10285657 | 0.86 | CCNT1 (0.41) | CDK9CCNT1 | |
| SCHEMBL1946243 | 0.84 | CCNT1 (0.54) | CDK9CCNT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | CDK9 16/4885CCNT1 39/4885SMN1; SMN2 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.